Tango Therapeutics Depreciation And Amortization Over Time

TNGX Stock  USD 3.10  0.16  5.44%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Tango Therapeutics Performance and Tango Therapeutics Correlation.
For more information on how to buy Tango Stock please use our How to Invest in Tango Therapeutics guide.
  
Depreciation And Amortization is likely to drop to about 1.6 M in 2024.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tango Therapeutics. If investors know Tango will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tango Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.15)
Revenue Per Share
0.402
Quarterly Revenue Growth
0.082
Return On Assets
(0.22)
Return On Equity
(0.49)
The market value of Tango Therapeutics is measured differently than its book value, which is the value of Tango that is recorded on the company's balance sheet. Investors also form their own opinion of Tango Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Tango Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tango Therapeutics' market value can be influenced by many factors that don't directly affect Tango Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tango Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tango Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tango Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Depreciation And Amortization Analysis

Compare Tango Therapeutics and related stocks such as Third Harmonic Bio, Cullinan Oncology LLC, and Edgewise Therapeutics Depreciation And Amortization Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
THRD11.1 M11.1 M11.1 M11.1 M11.1 M11.1 M11.1 M11.1 M11.1 M11.1 M11.1 M(10.6 M)(2.6 M)35 K36.8 K
CGEM43 K43 K43 K43 K43 K43 K43 K43 K43 K70 K62 K53 K93 K310 K325.5 K
EWTX123 K123 K123 K123 K123 K123 K123 K123 K123 K123 K185 K272 K538 K1.7 M1.8 M
RLYB247 K247 K247 K247 K247 K247 K247 K247 K247 K247 K62 K109 K167 K150 K117.6 K
GLUE348 K348 K348 K348 K348 K348 K348 K348 K348 K348 K537 K2.1 M8.6 M6.2 M3.9 M
CNTB790 K790 K790 K790 K790 K790 K790 K790 K790 K790 K221.1 K641 KM988 K803.8 K
TYRAKKKKKKKKKK47 K140 K296 K353 K185.7 K
RAPT1.4 M1.4 M1.4 M1.4 M1.4 M1.4 M1.4 M1.4 M1.2 M1.3 M1.1 M996 KM1.2 M952.3 K
XLO240 K240 K240 K240 K240 K240 K240 K240 K240 K240 K1.1 M1.5 M1.8 M1.9 M1.4 M
MLYS2.9 M2.9 M2.9 M2.9 M2.9 M2.9 M2.9 M2.9 M2.9 M2.9 M2.9 M18.7 M228.5 K167.9 K159.5 K
STTK255 K255 K255 K255 K255 K255 K255 K255 K255 K1.6 M618 K1.4 M3.1 MM4.2 M
KYMR205 K205 K205 K205 K205 K205 K205 K205 K205 K1.8 M1.8 M2.4 MM3.6 M2.3 M
NRIXMMMMMMMM2.4 M2.2 M6.1 M10.8 M13.7 M15.7 M16.5 M
RVMD1.2 M1.2 M1.2 M1.2 M1.2 M1.2 M1.2 M1.2 M1.8 M5.5 M6.5 M7.3 M9.7 M9.3 M6.5 M
BDTX24 K24 K24 K24 K24 K24 K24 K24 K44 K(14 M)600 K2.2 M3.2 M437 K458.9 K
PASG696 K696 K696 K696 K696 K696 K696 K696 K696 K10.3 M800 K1.5 M3.7 M3.7 M2.8 M
RLAY2.2 M2.2 M2.2 M2.2 M2.2 M2.2 M2.2 M2.2 M2.2 M2.8 M3.5 M3.9 M4.1 M5.3 MM
STOK113 K113 K113 K113 K113 K113 K113 K113 K214 K450 K888 K974 K1.5 M2.5 M2.6 M
PLRX666 K666 K666 K666 K666 K666 K666 K666 K666 K1.1 M1.3 M1.5 M3.7 M1.8 M1.9 M
ARVN436.3 K436.3 K436.3 K436.3 K436.3 K436.3 K436.3 K347.4 K706 K2.3 MMM8.2 M6.7 M3.9 M

Tango Therapeutics and related stocks such as Third Harmonic Bio, Cullinan Oncology LLC, and Edgewise Therapeutics Depreciation And Amortization description

The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.

My Equities

My Current Equities and Potential Positions

Tango Therapeutics
TNGX
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
LocationMassachusetts; U.S.A
ExchangeNASDAQ Exchange
USD 3.1

Additional Tools for Tango Stock Analysis

When running Tango Therapeutics' price analysis, check to measure Tango Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tango Therapeutics is operating at the current time. Most of Tango Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tango Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tango Therapeutics' price. Additionally, you may evaluate how the addition of Tango Therapeutics to your portfolios can decrease your overall portfolio volatility.